Modality
mRNA
MOA
Cl18.2
Target
DLL3
Pathway
Lipid Met
Prostate CaMMT2D
Development Pipeline
Preclinical
~Apr 2011
→ ~Jul 2012
Phase 1
~Oct 2012
→ ~Jan 2014
Phase 2
~Apr 2014
→ ~Jul 2015
Phase 3
~Oct 2015
→ ~Jan 2017
NDA/BLA
~Apr 2017
→ ~Jul 2018
Approved
Oct 2018
→ Sep 2029
ApprovedCurrent
NCT05160918
525 pts·Prostate Ca
2022-04→2025-01·Terminated
NCT06737708
1,353 pts·T2D
2018-10→2026-06·Completed
NCT04555539
2,934 pts·Prostate Ca
2023-11→2029-09·Terminated
+1 more trial
6,370 total pts3 indications
CompletedCurrentUpcoming
Catalysts (4)
2025-01-081.2y agoPh3 Readout· Prostate Ca
2026-06-163mo awayPh3 Readout· T2D
2026-06-213mo awayPh3 Readout· MM
2029-09-263.5y awayPh3 Readout· Prostate Ca
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Approved
Complet…
Approved
Termina…
Approved
Not yet…
Approved
Termina…
Catalysts
Ph3 Readout
2025-01-08 · 1.2y ago
Prostate Ca
Ph3 Readout
2026-06-16 · 3mo away
T2D
Ph3 Readout
2026-06-21 · 3mo away
MM
Ph3 Readout
2029-09-26 · 3.5y away
Prostate Ca
CompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05160918 | Approved | Prostate Ca | Terminated | 525 | 6MWD |
| NCT06737708 | Approved | T2D | Completed | 1353 | MRD |
| NCT04555539 | Approved | Prostate Ca | Terminated | 2934 | UPCR |
| NCT07664985 | Approved | MM | Not yet recr... | 1558 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 | |
| Tiratapinarof | Intellia | NDA/BLA | APOC3 |